Business Wire

CA-LIGHTBITS-LABS

23.6.2020 15:02:08 CEST | Business Wire | Press release

Share
Lightbits Labs Launches LightOS® 2.0 with High Availability

Lightbits Labs , the originator and leader in NVMe™ over TCP (NVMe/TCP) software-defined block storage, today launched LightOS® 2.0, enabling full cloud-native persistent storage integration for Kubernetes with unprecedented scaling and availability via clustering.

With the efficiency and convenience of all-flash arrays and the high performance of direct-attached flash storage, LightOS 2.0 enables independent scaling of compute and storage. This solution maximizes Kubernetes functionality, provides ease of migration and delivers fast recovery times following server failure. LightOS 2.0 provides virtual NVMe volumes, delivering low latency and high performance, while at the same time providing high availability via seamless target-side storage server failover. The result is no interruption in service or forced migration due to a drive or storage node failure.

“Lightbits Labs is the only storage solution in production in the market today that allows data centers to take full advantage of NVMe/TCP,” said Lip-Bu Tan, Lightbits Board Member and Founding Managing Partner of WRVI Capital. “The advancements in LightOS 2.0 will ensure that customers can easily scale their infrastructure, and in-turn their business, without compromising performance, efficiency, or cost.”

LightOS 2.0 leverages a Container Storage Interface (CSI) plugin for Kubernetes to address the growing need for third-party storage support for stateful container storage needs. This has become more important as Kubernetes microservices move from stateless to stateful applications. LightOS 2.0 is ideal for containerized environments like Kubernetes that require large-scale clusters with persistent and durable storage for rapid node migration, workload rebalancing, or recovery from failure without copying data over the network. If any computer node in the network fails, data is moved virtually by pointing it to another container. Taken together, LightOS 2.0 allows for lower TCO via higher capacity utilization as well as increased operational efficiency via decreased downtime and infrastructure flexibility.

“At cloud scale, everything fails. LightOS 2.0 is the industry’s first NVMe/TCP scale-out clustered storage solution – protecting against data loss and avoiding service interruptions at scale in the presence of SSD, server, storage, or network failures,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs . “Now containerized applications can enjoy all of the benefits of disaggregated storage using LightOS CSI plugin for Kubernetes, spinning up persistent storage volumes for containerized workloads just as easily as spinning up another container.”

When installed on commodity servers in large-scale data centers, LightOS 2.0 is automatically optimized for I/O intensive compute clusters, such as Kafka, Cassandra, MySQL, MongoDB, and time series databases. Each storage server in the cluster can support up to 64K namespaces and 16K connections. With LightOS 2.0 providing a highly available and durable storage layer, application teams can focus their efforts on developing new services while LightOS 2.0 takes care of the underlying whole storage platform, guaranteeing the availability of and high-performance access to the data.

“It’s clear that customers want on-demand, high performance, always-available storage no matter where their workloads run. As applications move to the edge, we’re excited about the potential of Lightbits LightOS 2.0 to leverage our rich, interconnected datacenter fabrics, providing local flash-style performance without the operational and reliability issues of server installed drives.” – Zachary Smith, Managing Director for Bare Metal, Equinix

LightOS 2.0 provides the following benefits:

  • Software-defined disaggregated storage for cloud data centers delivering direct-attached NVMe SSD performance and up to a 50% reduction in tail latency
  • Optimized for low-cost QLC flash: Extends write endurance of drives and improves write performance without the need to modify applications
  • Fast container migration via CSI persistent and durable storage
  • Standards-based NVMe/TCP block storage access protocol for application-server-to-storage-server communication
  • LightOS clusters leverage standard NVMe-oF 1.1 multipathing with data protection on the storage target side, providing transparency to the client with fast failover
  • Distributed and durable cluster management with fast failover handling
  • No single point of failure in data and control paths
  • Multiple LightOS clusters can exist in the same cloud data center and clients can use multiple clusters simultaneously
  • Support for Kubernetes v1.13 and v1.15 - v1.18 and later for any volume size, number of volumes or Kubernetes size cluster
  • Rolling upgrades allow for LightOS updates without disruption to storage clients
  • Target-side solution that is easy to deploy at scale, without having to touch the network infrastructure or the clients
  • In cases where Kubernetes is integrated with the OpenStack platform, LightOS 2.0 allows for stateful containers through Kubernetes via CSI, or via a Cinder plugin

“LightOS 2.0 is game changing for the data center. It transforms a rack of x86 servers with NVMe drives into a large high-performance highly redundant storage pool connected to applications servers via NVMe/TCP with Kubernetes integration and high availability. Everything is standard in the solution – TCP protocol on Ethernet, network switches, NICs and drivers – without the need to consider specialized and costly new network infrastructure. Thus LightOS protects current investments and boosts deployments at no risk to deliver new SLA levels for modern application workloads. This is the perfect illustration of the Software-Defined Storage philosophy,” says Philippe Nicolas, Analyst Coldago Research.

To learn more about LightOS 2.0, join our upcoming webinar on June 30th at 10 a.m. PT, “Kubernetes Assimilation: Persistence is Futile .” Josh Goldenhar, VP of Product Marketing, will discuss how you can deploy high performance, low latency block storage in Kubernetes environments and get great performance, increased reliability and lower cost. Register now to save your seat.

Lightbits Labs Resources

About Lightbits Labs™

Lightbits Labs, founded in 2016, is a software-defined storage company that brings hyperscale efficiency and flexibility to everyone. Lightbits’ solution delivers composable, disaggregated NVMe/TCP software-defined storage that performs like local Flash. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that from applications’ perspective is indistinguishable from local SSDs. Lightbits Labs is backed by strategic investors including Dell Technologies Capital, Cisco Investments and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye